Repligen to Report First Quarter 2025 Financial Results
Repligen (NASDAQ:RGEN) has scheduled its first quarter 2025 financial results announcement for Tuesday, April 29, 2025. The company will release its earnings press release before market opening, followed by a conference call at 8:30 a.m. ET to discuss business updates and financial results for the quarter ending March 31, 2025.
The conference call will be accessible via toll-free numbers: (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. A webcast will also be available through the company's Investor Relations website. Replay options include dial-in numbers (877) 344-7529 (US), (855) 669-9658 (Canada), and (412) 317-0088 (international) with passcode 6386085.
Repligen (NASDAQ:RGEN) ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per martedì 29 aprile 2025. La società pubblicherà il comunicato stampa sugli utili prima dell'apertura del mercato, seguito da una conference call alle 8:30 ET per discutere gli aggiornamenti aziendali e i risultati finanziari relativi al trimestre terminato il 31 marzo 2025.
La conference call sarà accessibile tramite numeri verdi: (844) 274-3999 per chiamate nazionali e (412) 317-5607 per chiamate internazionali. Sarà inoltre disponibile una trasmissione in streaming tramite il sito web delle Relazioni con gli Investitori della società. Le opzioni di replay includono numeri per richiamare: (877) 344-7529 (USA), (855) 669-9658 (Canada) e (412) 317-0088 (internazionale) con codice di accesso 6386085.
Repligen (NASDAQ:RGEN) ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el martes 29 de abril de 2025. La empresa publicará su comunicado de ganancias antes de la apertura del mercado, seguido de una llamada conferencia a las 8:30 a.m. ET para discutir actualizaciones comerciales y los resultados financieros del trimestre que finaliza el 31 de marzo de 2025.
La llamada conferencia estará disponible a través de números gratuitos: (844) 274-3999 para llamadas nacionales y (412) 317-5607 para llamadas internacionales. También habrá una transmisión en vivo disponible a través del sitio web de Relaciones con Inversionistas de la compañía. Las opciones de repetición incluyen números para marcar: (877) 344-7529 (EE.UU.), (855) 669-9658 (Canadá) y (412) 317-0088 (internacional) con el código de acceso 6386085.
Repligen (NASDAQ:RGEN)은 2025년 1분기 실적 발표를 2025년 4월 29일 화요일로 예정하고 있습니다. 회사는 시장 개장 전에 실적 보도자료를 발표하며, 이어서 동부 표준시 기준 오전 8시 30분에 컨퍼런스 콜을 통해 2025년 3월 31일로 마감되는 분기의 사업 업데이트 및 재무 결과를 논의할 예정입니다.
컨퍼런스 콜은 국내 발신자는 (844) 274-3999, 국제 발신자는 (412) 317-5607의 무료 전화번호를 통해 접속할 수 있습니다. 또한 회사 투자자 관계 웹사이트를 통해 웹캐스트도 제공될 예정입니다. 재청취 옵션으로는 회선 접속 번호 (미국) (877) 344-7529, (캐나다) (855) 669-9658, (국제) (412) 317-0088과 접속 코드 6386085가 제공됩니다.
Repligen (NASDAQ:RGEN) a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le mardi 29 avril 2025. La société publiera son communiqué de résultats avant l'ouverture des marchés, suivi d'une conférence téléphonique à 8h30 ET pour discuter des mises à jour commerciales et des résultats financiers du trimestre se terminant le 31 mars 2025.
La conférence téléphonique sera accessible via des numéros verts : (844) 274-3999 pour les appels nationaux et (412) 317-5607 pour les appels internationaux. Un webcast sera également disponible sur le site des Relations Investisseurs de la société. Les options de replay incluent des numéros de rappel : (877) 344-7529 (États-Unis), (855) 669-9658 (Canada) et (412) 317-0088 (international) avec le code d'accès 6386085.
Repligen (NASDAQ:RGEN) hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für Dienstag, den 29. April 2025, geplant. Das Unternehmen wird die Gewinnmitteilung vor Markteröffnung veröffentlichen, gefolgt von einer Telefonkonferenz um 8:30 Uhr ET, um Geschäftsaktualisierungen und die Finanzergebnisse für das Quartal zum 31. März 2025 zu besprechen.
Die Telefonkonferenz ist über gebührenfreie Nummern erreichbar: (844) 274-3999 für Anrufer innerhalb der USA und (412) 317-5607 für internationale Anrufer. Ein Webcast wird ebenfalls über die Investor-Relations-Website des Unternehmens verfügbar sein. Wiederholungsoptionen umfassen Einwahlnummern (877) 344-7529 (USA), (855) 669-9658 (Kanada) und (412) 317-0088 (international) mit dem Zugangscode 6386085.
- None.
- None.
Webcast and Conference Call to Be Held Tuesday, April 29, 2025, at 8:30 a.m. ET
WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2025 financial results on Tuesday, April 29, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- month reporting period ended March 31, 2025.
The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the U.S., (855) 669-9658 for callers in Canada and (412) 317-0088 for international callers. Replay listeners must provide the passcode 6386085.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
(781) 419-0204
investors@repligen.com
FAQ
When will Repligen (RGEN) report Q1 2025 earnings?
How can investors access Repligen's (RGEN) Q1 2025 earnings call?
What is the replay passcode for Repligen's (RGEN) Q1 2025 earnings call?
What period will Repligen's (RGEN) Q1 2025 financial results cover?
